SCHEMBL6081115

SCHEMBL6081115

NC(CCC(=O)c1ccccc1)c1cc(C(=O)O)nc2c(O)cccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.36
CCR6 P51684 1/20 0.34
IGFBP3 P17936 3/20 0.34
MMP2 P08253 1/20 0.33
GLA P06280 1/20 0.33
FDPS P14324 1/20 0.33
PIM1 P11309 1/20 0.33
TNKS O95271 1/20 0.33
PARP1 P09874 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
KDM4A O75164 1/20 0.33
RAB9A P51151 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
HIF1AN Q9NWT6 1/20 0.33
ANPEP P15144 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6593208 0.83 MRGPRX4 (0.45) KMT2ARAB9AMAPT
SCHEMBL6079871 0.76 CCR6 (0.35) KDM4EKMT2ACYP1A2CCR6GLA
SCHEMBL6081112 0.74 KDM4E (0.40) KDM4EKMT2ACYP1A2CCR6IGFBP3
SCHEMBL4309921 0.73 KDM4E (0.49) KDM4EKMT2ACYP1A2CCR6IGFBP3
Xanthurenate SCHEMBL379760 0.70 KDM4E (0.59) KDM4EKMT2ACYP1A2CCR6IGFBP3
Xanthurenate SCHEMBL29394132 0.70 KDM4E (0.59) KDM4EKMT2ACYP1A2CCR6IGFBP3
Xanthurenate SCHEMBL29911018 0.70 KDM4E (0.59) KDM4EKMT2ACYP1A2CCR6IGFBP3
SCHEMBL6079537 0.70 KDM4E (0.54) KDM4EKMT2ACYP1A2IGFBP3FDPS
SCHEMBL6079734 0.68 MMP2 (0.54) KDM4EKMT2ACYP1A2CCR6IGFBP3
SCHEMBL6079288 0.67 KDM4E (0.51) KDM4EKMT2ACYP1A2CCR6IGFBP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL KDM4E 1006/4885KMT2A 1384/4885CYP1A2 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.